Evolent Health, Inc. 8-K Summary
Business Context and Reporting Period
This Form 8-K reports on the results of Evolent Health, Inc.'s 2017 Annual Meeting of Stockholders held on June 8, 2017. The filing date is June 9, 2017. The company is incorporated in Delaware and is designated as an emerging growth company.
Key Financial Metrics
This filing does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. It is a corporate governance report regarding shareholder voting outcomes.
Material Changes and Voting Results
As of the record date of April 18, 2017, there were 57,040,976 shares of Class A common stock and 10,948,832 shares of Class B common stock outstanding. Stockholders voted on two proposals:
- Proposal 1: Election of Directors. Stockholders elected three Class II director nominees (Matthew Hobart, Diane Holder, and Michael D'Amato) to three-year terms expiring at the 2020 annual meeting. All nominees received a majority of votes cast.
- Proposal 2: Ratification of Auditors. Stockholders ratified the appointment of PricewaterhouseCoopers LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2017.
Guidance, Outlook, and Risks
The filing does not provide management commentary, financial guidance, outlook, or specific risk factors. It strictly details the voting tallies for the annual meeting proposals.
Investor Verification Checklist
- Verify the final voting percentages for the three director nominees to assess shareholder support for the board composition.
- Confirm the ratification of PricewaterhouseCoopers LLP as the independent auditor for the 2017 fiscal year.
- Review the definitive proxy statement on Schedule 14A (filed April 27, 2017) for detailed biographies of the elected directors and the rationale for the auditor appointment.
- Note the total number of non-votes (4,991,820) for the director elections, which may indicate broker non-votes or abstentions on specific matters.